ArticleAmerican journal of hematology2025

Efficacy and Safety of the Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation.

Xiaoyu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.